JP2020530446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530446A5 JP2020530446A5 JP2020505383A JP2020505383A JP2020530446A5 JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5 JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- optionally substituted
- compound according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211691A JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543307P | 2017-08-09 | 2017-08-09 | |
| US62/543,307 | 2017-08-09 | ||
| US201762553728P | 2017-09-01 | 2017-09-01 | |
| US62/553,728 | 2017-09-01 | ||
| US201762608504P | 2017-12-20 | 2017-12-20 | |
| US62/608,504 | 2017-12-20 | ||
| PCT/US2018/045868 WO2019032743A1 (en) | 2017-08-09 | 2018-08-08 | COMPOUNDS, COMPOSITIONS AND METHODS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Division JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530446A JP2020530446A (ja) | 2020-10-22 |
| JP2020530446A5 true JP2020530446A5 (https=) | 2021-09-16 |
Family
ID=65272557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505383A Withdrawn JP2020530446A (ja) | 2017-08-09 | 2018-08-08 | 化合物、組成物、及び、方法 |
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11236100B2 (https=) |
| EP (1) | EP3665156A4 (https=) |
| JP (3) | JP2020530446A (https=) |
| KR (2) | KR20250017299A (https=) |
| CN (3) | CN118239937A (https=) |
| AU (3) | AU2018313850B2 (https=) |
| CA (1) | CA3071024A1 (https=) |
| CL (1) | CL2020000299A1 (https=) |
| CO (1) | CO2020001220A2 (https=) |
| CR (1) | CR20200054A (https=) |
| IL (2) | IL272089B2 (https=) |
| MA (1) | MA49858A (https=) |
| MX (2) | MX2020001352A (https=) |
| MY (1) | MY201438A (https=) |
| PE (1) | PE20200834A1 (https=) |
| PH (1) | PH12020550028B1 (https=) |
| SA (1) | SA520411222B1 (https=) |
| SG (1) | SG11202000532SA (https=) |
| TW (1) | TW201920115A (https=) |
| WO (1) | WO2019032743A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3959198A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| PE20220572A1 (es) * | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| JP7699595B2 (ja) | 2020-01-28 | 2025-06-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| CN115190813B (zh) * | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| RS66455B1 (sr) | 2020-10-22 | 2025-02-28 | Evotec Int Gmbh | Modulatori puta integrisanog odgovora na stres |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CN117580824A (zh) * | 2020-10-30 | 2024-02-20 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| IL302440A (en) * | 2020-10-30 | 2023-06-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
| CN116507608A (zh) * | 2020-11-20 | 2023-07-28 | 戴纳立制药公司 | 化合物、组合物和方法 |
| JP2023551474A (ja) * | 2020-11-25 | 2023-12-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の処置および予防のための芳香族架橋環アミド誘導体 |
| PE20231440A1 (es) * | 2020-12-18 | 2023-09-14 | Denali Therapeutics Inc | Formas solidas de un compuesto |
| WO2023250107A1 (en) * | 2022-06-23 | 2023-12-28 | Denali Therapeutics Inc. | Process for preparing modulators of eukaryotic initiation factor 2b |
| AU2023384649A1 (en) * | 2022-11-21 | 2025-05-22 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof |
| WO2025019827A1 (en) * | 2023-07-20 | 2025-01-23 | Denali Therapeutics Inc. | Formulation, solid dosage form, and methods |
| WO2025230528A1 (en) * | 2024-05-01 | 2025-11-06 | Calico Life Sciences Llc | Methods of treating amyotrophic lateral sclerosis |
| WO2026004939A1 (ja) * | 2024-06-28 | 2026-01-02 | キッセイ薬品工業株式会社 | ジ置換ビシクロ［１．１．１］ペンタン化合物 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| AU762345B2 (en) | 1998-10-16 | 2003-06-26 | Asubio Pharma Co., Ltd. | Aminophenoxyacetic acid derivatives as neuroprotectants |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| AU2001249417A1 (en) | 2000-04-26 | 2001-11-07 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| WO2002080928A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| BRPI0514893A (pt) | 2004-09-02 | 2007-11-27 | Vertex Pharma | quinazolinas úteis como moduladores de canais de ìon |
| EP1891078A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| CA2666482A1 (en) | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| ATE520687T1 (de) | 2007-06-15 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyranderiva e |
| CN102232078B (zh) | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
| WO2010138820A2 (en) | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| RS57869B1 (sr) | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| AU2012226890B2 (en) | 2011-03-10 | 2016-10-06 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| SMT202400031T1 (it) * | 2011-04-22 | 2024-03-13 | Signal Pharm Llc | Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse |
| BR112014019622B8 (pt) | 2012-02-14 | 2020-05-26 | Syngenta Participations Ag | composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas |
| WO2014054635A1 (ja) | 2012-10-02 | 2014-04-10 | 大日本住友製薬株式会社 | イミダゾール誘導体 |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| CN106999451B (zh) | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| CA2964982C (en) * | 2014-11-20 | 2022-07-05 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| HK1248069A1 (zh) | 2015-02-25 | 2018-10-12 | William Marsh Rice University | 去乙酰氧基微管溶素h及其类似物 |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| EA201792421A1 (ru) | 2015-05-05 | 2018-05-31 | Байер Фарма Акциенгезельшафт | Амидозамещенные производные циклогексана |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015492A (ko) | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| US20190298705A1 (en) | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| ES2925186T3 (es) * | 2016-07-06 | 2022-10-14 | Acquist Llc | Compuestos y su uso para reducir los niveles de ácido úrico |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| JP7128816B2 (ja) | 2016-12-08 | 2022-08-31 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤 |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| EP3649108A1 (en) | 2017-07-03 | 2020-05-13 | GlaxoSmithKline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| BR112020000122A2 (pt) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2019054430A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| WO2019090090A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP2021501781A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019090074A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2020012339A1 (en) | 2018-07-09 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202111970WA (en) | 2019-04-30 | 2021-11-29 | Calico Life Sciences Llc | Substituted cyclolakyls as modulators of the integrated stress pathway |
| PE20220572A1 (es) | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| PE20231440A1 (es) | 2020-12-18 | 2023-09-14 | Denali Therapeutics Inc | Formas solidas de un compuesto |
-
2018
- 2018-08-08 CA CA3071024A patent/CA3071024A1/en active Pending
- 2018-08-08 PE PE2020000174A patent/PE20200834A1/es unknown
- 2018-08-08 CR CR20200054A patent/CR20200054A/es unknown
- 2018-08-08 WO PCT/US2018/045868 patent/WO2019032743A1/en not_active Ceased
- 2018-08-08 MX MX2020001352A patent/MX2020001352A/es unknown
- 2018-08-08 IL IL272089A patent/IL272089B2/en unknown
- 2018-08-08 KR KR1020257001611A patent/KR20250017299A/ko active Pending
- 2018-08-08 AU AU2018313850A patent/AU2018313850B2/en active Active
- 2018-08-08 EP EP18844666.0A patent/EP3665156A4/en active Pending
- 2018-08-08 JP JP2020505383A patent/JP2020530446A/ja not_active Withdrawn
- 2018-08-08 IL IL301709A patent/IL301709B2/en unknown
- 2018-08-08 CN CN202410183135.XA patent/CN118239937A/zh active Pending
- 2018-08-08 KR KR1020207005952A patent/KR102757890B1/ko active Active
- 2018-08-08 CN CN202410187269.9A patent/CN118239938A/zh active Pending
- 2018-08-08 PH PH1/2020/550028A patent/PH12020550028B1/en unknown
- 2018-08-08 MY MYPI2020000561A patent/MY201438A/en unknown
- 2018-08-08 MA MA049858A patent/MA49858A/fr unknown
- 2018-08-08 US US16/637,718 patent/US11236100B2/en active Active
- 2018-08-08 CN CN201880055607.6A patent/CN111094233B/zh active Active
- 2018-08-08 SG SG11202000532SA patent/SG11202000532SA/en unknown
- 2018-08-09 TW TW107127864A patent/TW201920115A/zh unknown
-
2020
- 2020-01-31 MX MX2023003989A patent/MX2023003989A/es unknown
- 2020-02-02 SA SA520411222A patent/SA520411222B1/ar unknown
- 2020-02-03 CL CL2020000299A patent/CL2020000299A1/es unknown
- 2020-02-03 CO CONC2020/0001220A patent/CO2020001220A2/es unknown
-
2021
- 2021-11-19 US US17/531,039 patent/US11851440B2/en active Active
-
2022
- 2022-12-28 JP JP2022211691A patent/JP2023052166A/ja not_active Withdrawn
-
2023
- 2023-03-22 AU AU2023201775A patent/AU2023201775A1/en not_active Abandoned
-
2024
- 2024-12-19 JP JP2024223976A patent/JP2025031810A/ja active Pending
-
2025
- 2025-01-08 US US19/014,044 patent/US20250388595A1/en active Pending
- 2025-01-31 AU AU2025200658A patent/AU2025200658A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530446A5 (https=) | ||
| TWI724079B (zh) | 可溶性鳥苷酸環化酶刺激劑 | |
| US20230121195A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| JP2020532506A5 (https=) | ||
| JP5728487B2 (ja) | 三環式ヘテロ環化合物 | |
| US20100280082A1 (en) | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | |
| US11254663B2 (en) | Substituted bicyclic compounds as farnesoid X receptor modulators | |
| JP2017193592A5 (https=) | ||
| JP2021517893A5 (https=) | ||
| JP5602230B2 (ja) | スフィンゴシン−１−リン酸受容体アゴニスト | |
| JP2009525340A5 (https=) | ||
| JP2018529745A (ja) | Ｎｒｆ２レギュレーターとしてのビアリールピラゾール | |
| EP2863914A1 (en) | Pyrazolyl derivatives as syk inhibitors | |
| JP2012515789A (ja) | スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体 | |
| JP2021535137A5 (https=) | ||
| JP2017523223A5 (https=) | ||
| JP2014525467A (ja) | Ｐｄｅ１０モジュレーター | |
| JP2020520925A5 (https=) | ||
| KR20210032936A (ko) | Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물 | |
| JPWO2020047312A5 (https=) | ||
| JPWO2020002950A5 (https=) | ||
| WO2015155566A1 (en) | Fused pyrazole compounds as cb1r antagonists and uses thereof | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 | |
| JPWO2023053015A5 (https=) |